Production (Stage)
Rakovina Therapeutics Inc.
RKVTF
$0.0383
$0.00061.59%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 161.25% | 61.90% | 40.43% | 18.75% | 55.56% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 104.94% | 57.81% | 26.87% | 7.25% | 1.08% |
| Operating Income | -104.94% | -57.81% | -26.87% | -7.25% | -1.08% |
| Income Before Tax | -99.53% | -54.41% | -33.95% | -17.62% | -11.38% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -99.53% | -54.41% | -33.95% | -17.62% | -11.38% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -99.53% | -54.41% | -33.95% | -17.62% | -11.38% |
| EBIT | -104.94% | -57.81% | -26.87% | -7.25% | -1.08% |
| EBITDA | -132.59% | -75.48% | -35.36% | -8.78% | -1.44% |
| EPS Basic | -39.47% | -20.29% | -32.81% | -17.65% | -11.76% |
| Normalized Basic EPS | -35.42% | -20.93% | -32.50% | -19.05% | -11.63% |
| EPS Diluted | -71.05% | -10.67% | -14.86% | -8.11% | -11.76% |
| Normalized Diluted EPS | -35.42% | -20.93% | -32.50% | -19.05% | -11.63% |
| Average Basic Shares Outstanding | 43.36% | 28.45% | 1.29% | 0.37% | 0.11% |
| Average Diluted Shares Outstanding | 43.36% | 28.45% | 1.29% | 0.37% | 0.11% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |